Evaluation the effect of oral capsule of Peganum harmala seed on bone density in menopausal women prone to osteoporosis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017091910222N12

Enrollment

Registered

2017-10-22

Start date

2017-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoprosis. Osteopathies and chondropathies

Interventions

Intervention 1: the first group: receive peganum harmala capsules 500 mg twice daily with routine treatment. Intervention 2: the second group receive only routine treatment .

Treatment - Drugs

the first group: receive peganum harmala capsules 500 mg twice daily with routine treatment

the second group receive only routine treatment .

Eligibility

Sex/Gender

Female

Age

45 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Postmenopausal women who at least 12 month past after amenorrhea without correlation with pregnancy, breast-feeding or other hormonal disorders ;prone to osreoprosis with T score of less than 2.5 in bone density measurement. Exclusion criteria: Gastrointestinal absorption disorder; Thyroid patients; Kidney and liver diseases

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
T score. Timepoint: 3 month after intervention. Method of measurement: Bondensitometry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMorteza Dehghan

Shahrekord University of Medical Sciences

dehghan_mortaza@yahoo.com+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026